CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Pharmaceutical Technology
Original article

KymaThera pulls in $80m to bring breast cancer drug to clinic 

Phase 1K-1728Positive
AI Analysis

Summary

KymaThera secured $80 million in funding to support its Phase 1 trial of K-1728, an oral PI3Kα inhibitor for breast cancer, with first patient dosing planned for Q4 2026.

Clinical Trial Data

Phase

Phase 1

Importance:6/10
Sentiment:
0.60
financingPhase 1breast cancerPI3K inhibitororal therapy
Related Companies

Read the original article

Published by Pharmaceutical Technology on October 7, 2026 10:15 AM

Read Original